NanoEcho
0.04 SEK
-0.51 %
Less than 1K followers
NANECH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.51 %
-13.00 %
-10.19 %
-48.81 %
-30.33 %
-62.92 %
-
-
-74.13 %
NanoEcho operates in the healthcare sector, with a primary focus on rectal cancer diagnostics. The company is currently in the clinical stage, developing a new diagnostic method to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide an accurate diagnosis and personalized treatment. NanoEcho was founded in 2013 and is headquartered in Lund.
Read moreMarket cap
18.08M SEK
Turnover
27.07K SEK
Revenue
488K
EBIT %
-3,030.53 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/5
2026
General meeting '26
25/8
2026
Interim report Q2'26
27/10
2026
Interim report Q3'26
All
Press releases
3rd party
ShowingAll content types
NanoEchos forskningssystem vid Lunds universitet är klart för användning
NanoEcho startar analysfasen av den inledande delen av Proof of Concept-studien
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools